Lead Product(s): Azasetron
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2020
Patient recruitment rates from this trial now indicate the data will be available by mid-year 2021, which is later than previously announced.